As both TRα and TRβ are expressed in different histological subtypes of ovarian cancer cells, it is crucial to evaluate their effects on rare OC and examine the potential use of TR inhibitors as targeted therapy in rare OC. Here, THRB is linked to ovarian carcinoma.